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INTRODUCTION 
Coronary Artery disease is epidemic in our country. It is reported 
that CHD accounts for 32% of adult death in 2010-2013 in our country. 
In India there has been 4 fold increase in prevalence of coronary heart 
disease in last 40 year. Important risk factors are diabetes, hypertension, 
smoking, dyslipidemia, abdominal obesity, unhealthy diet, physical 
inactivity. Rapid urbanisation and change in life style in last two decade 
have led to growing burden of coronary heart disease.  
Acute Coronary Syndrome (ACS) is a broad collection of condition 
 Acute Myocardial Infarction which manifest either as ST Elevation 
MI (STEMI) and  Non ST Elevation myocardial infarction 
(NSTEMI). 
 Unstable angina( UA). 
 Notably, the clinical presentation and symptoms may be similar 
for all these syndromes. 
 The primary goals of treatment in ACS are relieve or limit 
ischemia, prevent reinfarction, improves outcome and well being.  
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Acute Myocardial infarction manifests as either ST segment 
elevation myocardial infarction (STEMI) or Non ST segment elevation 
myocardial infarction (NSTEMI).Risk stratification of acute myocardial 
infarction are done by various clinical assessment and score .KILLIP 
Classification is used assess the severity and prognosis in acute 
myocardial infarction .Serum uric acid which is a metabolite of purine 
often used as a biomarker of inflammation. Hyperuricemia are associated 
with various diseases such as chronic kidney disease, stroke, 
cardiovascular disease. The purpose of  this study is to assess the 
correlation between serum uric acid and killip class in acute myocardial 
infarct. 
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AIM AND OBJECTIVES 
AIM: 
To study the association between Serum Uric acid level and killip 
class in acute myocardial infarction. 
OBJECTIVES 
1. To assess the serum uric acid in level in acute myocardial 
infarction. 
2. To study the association between serum uric acid level an killip 
class in acute myocardial infarction 
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REVIEW OF LITERATURE 
ACUTE MYOCARDIAL INFARCTION 
The current universal definition for acute myocardial infarction 
adopted by ESC/ACF (American Cardiology Foundation) as evidence of 
myocardial necrosis in a clinical setting  consistent. Under these 
condition any of following criteria meet the diagnosis of MI 
1. Detection of  rise and/or fall in cardiac biomarkers preferably 
troponin c with at least one value above the 99th percentile of upper 
reference limit with one of the following  
 Ischemic symptoms. 
 New significant ST segment T wave changes or  new left bundle 
branch block. 
 Pathological Q wave on the ECG. 
 Imaging evidence of new loss of viable myocardium or regional 
wall motion abnormality. 
 Intracoronary thrombus identification by angiography or autopsy.  
2. PCI related MI-Elevation of cardiac troponin to >5 times of 99th 
percentile of upper normal limit.  
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3. CABG related MI-Elevation of cardiac troponin to >10 times of 
99th percentile of the upper normal limit. 
 The patients included in acute myocardial infarction are either have 
 ST segment elevation MI(STEMI)   
 Non ST segment elevation MI(NSTEMI). 
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EPIDEMIOLOGY 
 Acute Myocardial Infarction is the leading cause of mortality in 
both developed and developing nation such as India. 
 A significant proportion of these patients will die from sudden 
cardiac death due to ventricular arrhythmia prior to arriving at the 
hospital. 
 The success of the medical community’s concerted efforts has led 
to 26% reduction in mortality since 1990 
 The risk factors are hypertension, diabetes, smoking, dyslipidemia, 
abdominal obesity, sedentary life style, male gender. 
 90% of acute myocardial infarction are attributed to modifiable risk 
factors. 
 Overall survival rates in majority of good Indian centers are  > 
90%. 
 There are various predictors of mortality in acute myocardial 
infarction such as killip class,TIMI score by baseline clinical data. 
 
 
 
 
 
 
 
 16 
 
 
BLOOD SUPPLY OF HEART 
 Coronary artery are the first branch that arises from the aorta,  it 
arise from the sinuses of Valsalva just above the aortic valve. 
 Right coronary artery (RCA) arises from the anterior sinus 
and  supplies  
1. Right atrium. 
2. Greater part of Right ventricle. 
3. Posterior region of inter ventricular septum 
4. Conduction system in 40% of the patients 
5. Small part of left ventricle adjacent to posterior inter ventricular 
groove. 
 
 
 
 
 
 
 
 17 
 
 
 
 
 
 
                  
 18 
   
  Left coronary artery (LCA) arises from left posterior sinus, 
divides into the left anterior descending artery and circumflex 
artery. It supplies  
1. Left atrium.  
2. Greater part of left ventricle. 
3. Anterior region of interventricular septum 
4. Small part of right ventricle adjacent to anterior inter ventricular 
groove. 
5. Part of left branch of AV bundle. 
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PATHOPHYSIOLOGY OF STEMI 
 STEMI occurs due to sudden decrease in coronary blood flow after 
thrombotic occlusion of  coronary artery. 
 STEMI occurs when coronary artery thrombus develops quickly at 
the site of vascular injury produced by various factors such as 
smoking, hypertension, accumulation of lipid. 
 In many cases atherosclerotic plaque surface will be disrupted 
which leads to thrombogenesis by activation of coagulation 
cascade, generation of thromboxane A2, activation of platelets. 
 Other condition that can cause STEMI are 
1. Severe coronary vasospasm. 
2. Coronary artery embolisation. 
3. Spontaneous coronary dissection. 
 These conditions should be considered in a patient whose clinical 
findings suggest a process other than acute plaque rupture. 
 The factors responsible for myocardial damage are territory 
supplied by culprit vessel, duration of occlusion, percentage of 
occlusion, blood supplied by collaterals, myocardial oxygen 
demand,  
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PATHOPHYSIOLOGY OF NSTEMI 
 Pathogenesis of NSTEMI four processs: 
1. Rupture of unstable atheromatous plaque. 
2. Vasoconstriction of coronary artery. 
3. Imbalance between myocardial oxygen supply and demand 
4. Gradual intra luminal narrowing of epicardial coronary artery 
 Plaque ruptue or erosion leads to formation of superimposed 
thrombus along with impaired myocardial perfusion and 
vasoconstriction leads to myocardial necrosis. 
 Activation of coagulation cascade and platelet plays a important 
role in both STEMI and NTEMI. 
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ATHEROSCLEROSIS 
 Endothelial cells activated by risk factors which include 
hyperlipoproteinemia, usually express adhesion and chemo 
attractant molecules, recruit inflammatory leucocytes such as 
monocytes and T lymphocytes. Extracellular lipid begins to 
accumulate in intima. 
 Fibrofatty stage- monocyte recruited to artery wall becomes 
macrophages and express scavenger receptors that bind modified 
lipoproteins. Macrophages become lipid laden foam cells by 
engulfing modified lipoproteins. Leucocytes and resident vascular 
wall cells can secrete cytokines and growth factors that increase 
leucocyte migration and smooth muscle cell migration and 
proliferation. 
 As lesion progress, inflammatory meditors causes expression of 
tissue factors, a potent pro-coagulant and matrix degrading 
proteinases that weaken fibrous cap of plaque. 
 When fibrous cap rupture at the point of weakness,coagulation 
factors have access to thrombogenic tissue factors causing 
thrombosis and non occlusive plaque. 
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 If balance between prothrombotic and firinolytic mechanism 
prevailing at that particular region and at that particular time is 
unfavourable occlusive thrombus causing myocardial infarction. 
FEATURES OF VULNERABLE PLAGUE: 
Lipid rich core ( > 30-40% of plague). 
Fibrous cap covering the lipid rich core. 
Thikness of plague<100 µm. 
Many macrophages. 
Few smooth muscle cells. 
Outward remodelling preserving the lumen. 
Neovascularisation from vasa vasorum. 
Adventitial/perivascular inflammation. 
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CLINICAL FEATURES 
 Predisposing factors 
1. 50% of the patients with STEMI usually have an identifiable 
precipitating factors and prodromal symptoms. 
2. Unusually heavy exercise and emotional stress would precipitate 
STEMI. 
3. Other precipitating factors are lung infections, hypoxemia, 
pulmonary embolism, hypoglycaemia, administration of ergot, 
serum sickness, sympathomimetics, allergy. 
4. Onset of STEMI  have a circadian periodicity, with peak incidence 
of events occurring in the morning, these early morning hours are 
associated with increase cortisol and catecholamines, aggregation 
of platelet. These circadian rhythm will be absent in patients on 
beta blockers and aspirin. 
 Symptoms  
1. Chest pain generally lasts more than half an hour, pain usually 
described as constricting, crushing, compressing or sensation of 
heaviness on chest. 
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2. Chest pain localised to retrosternal region and spread to both 
anterior chest wall commonly left side, pain radiates to left 
shoulder, neck, jaw and interscapular region. 
 Nausea and vomiting can occur, due to vagal reflex activation, 
stimulation of left ventricular receptors. This symptoms are 
commonly seen  inferior wall myocardial infarction. This 
symptoms can be confused with gastritis, peptic ulcer, 
cholecystitis. 
 Other associated symptoms are dizziness, palpitations, cold 
perspiration, sense of impending doom. 
 ATYPICAL PRESENTATION 
1. Features of heart failure. 
2. Classical angina pain. 
3. Atypical pain location. 
4. Sudden onset of mania and psychosis 
5. Syncope. 
6. Features resembling of stroke. 
7. Apprehension and nervousness. 
 Clinical features of NSTEMI resembles same as STEMI. 
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PHYSICAL EXAMINATION 
 Physical examination is important in determining other sources of 
chest pain, assessing prognosis and establishing a baseline that will 
aid in early recognition of complications. 
 The goal is to determine hemodynamic instability, presence of 
cardiogenic pulmonary edema, or mechanical complication such as 
papillary muscle dysfunction, free wall rupture, ventricular septal 
defect and to exclude other causes of chest pain. 
 Physical examination should include intial assessment of vital 
signs,oxygenation, bilateral blood pressure and jugular venous 
pulse, bilateral crepitation for pulmonary edema, murmur or 
friction rub and gallop for mechanical complication and heart 
failure, and neurological examination.    
 Fundus examination may provide underlying vascular status due to 
hypertension and diabetes. Abdomen examination may provide 
right heart failure features such as hepatomegaly and positive 
abdominojugular reflex. Examination of extremities will be useful 
in identifying peripheral vascular disease and cyanosis in severe 
LV failure. 
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DIAGNOSTIC TESTS 
ELECTROCARDIOGRAM (ECG) 
 The ECG should be performed and interpreted within 10 mins of 
presentation. 
 Serial standard 12-lead ECG is extremely useful in detection and 
localisation of myocardial infarction 
 Analysis of the constellation of ECG showing ST changes will be 
useful in identifying the site of occlusion in the infarct artery. 
 In addition to diagnostic and prognostic information,serial 12-lead 
ECG monitoring will provide non invasive information about the 
success of reperfusion therapy. 
 ECG CRITERIA FOR DIAGNOSIS STEMI: 
 New ST ELEVATION at J point in two or more contiguous 
leads with (in the absence of LBBB) 
 >1mm(.1Mv ) in all leads except V2-V3. 
 In leads V2-V3 - >2mm(.2mv) in men > 40 years of age. 
                            >2.5mm(.25mv) in men <40 years of age. 
                            >1.5mm(.15mv) in women. 
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 In the setting of an old LBBB, acute myocardial infarction is 
diagnosed by Sgarbossa criteria 
1.  ST-segment elevation >1mm and concordant with 
QRS complex-5 points. 
2. ST-segment depression >1mm in lead V1,V2,V3 -3 
points. 
3. ST-segment elevation >5mm and discordant with QRS 
complex-2points. 
 Score more than 3 has specificity of 98% for acute myocardial 
infarction. 
 
 
 
 29 
 ECG CRITERIA FOR DIAGNOSIS OF NSTEMI 
1.  New ST- segment depression ( downsloping or horizontal ) 
>0.05mv in two contiguous leads. 
2. T-wave inversion >.1mv in two contiguous leads with prominent R 
wave  
or with R/S ratio >1 
 
 
LOCALISATION OF MI. 
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EXTENSIVE ANTERIOR WALL MI. 
 
ACUTE LATERAL WALL MI 
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ACUTE INFERIOR WALL MI 
 
NSTEMI OF ANTERIOR WALL 
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LEFT BUNDLE BRANCH BLOCK. 
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 Posterior myocardial infarction is an entity that is often 
unrecognized, it should be suspected in the patients with inferior of 
lateral wall myocardial infarction. 
 The “reverse mirror test” is useful to identify posterior wall 
myovardial infarction, ST segment depression in leads V1to V3 is 
actually a ST elevation in posterior wall. The prominent R wave is 
actually represent posterior Q wave. 
 Inferoposterior or inferolateral myocardial infarction involves the 
right coronary artery(RCA) or left circumflex obtuse marginal 
branch. 
 There are condition that mimic electrocardiographic changes of 
myocardial infarction, it is termed as “pseudoinfarction”. They are 
1. Ventricular hypertrophy.  
2. Preexitation syndrome. 
3. Primary myocardial disease. 
4. Pneumothorax, Pulmonary embolism. 
5. Primary and metastatic tumors of heart. 
6. Amyloid disease, cardiac sarcoidisis. 
7. Intracranial hemorrhage. 
8. Hyperkalemia. 
9. Pericarditis. 
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IMAGING 
CHEST RADIOGRAPHY: 
 A standard chest radiography ( CXR ) should be included in 
initial evaluation. Pulmonary edema in CXR us important 
prognostic and therapeutic implications. prominent vascular 
markings in CXR reflects elevated LV end diastolic pressure. 
    ECHOCARDIOGRAPHY: 
 The evaluation of a patient with a non diagnostic ECG, Finding 
of  echocardiography such as regional wall motion abnormality 
can support the diagnosis of myocardial infarction. It also useful 
in localising the territory at risk. 
 LV function assessed in echocardiography correlates well with 
measurements in angiography are useful in establishing 
prognosis in myocardial infarction. 
 Echocardiography can help in detecting in mechanical 
complication of MI such as mitral regurgitation, ventricular 
septal rupture, cardiac tamponade. 
 
 
 35 
CARDIAC BIOMARKERS 
Markers of myocardial necrosis: 
Myocardial injury can be detected by presence of circulating 
proteins in serum which is released by damaged myocardium. Most 
commonly used serum markers are cardiac specific troponin and creatine 
kinase MB. 
Cardiac specific troponins: 
The preferred  marker to detect myocardial injury is cardiac 
troponin which consists of three subunits that regulate calcium mediated 
contractile process of striated muscle. Troponin I binds to actin and 
inhibits interaction of actin-myosin. Troponin T binds to tropomysin 
thereby attaching the troponin complex to thin filaments. Only cardiac 
specific isoforms of troponin T(cTnT)  and troponin I(cTnI) are 
exclusively expressed in cardiac myocyte. 
In myocardial infarction, cardiac specific troponin T and I begin to 
rise 3 hours after onset of chest discomfort. It may persist for 7 to 10 days 
in myocardial infarction patients because of continuous proteolysis of 
contractile apparatus in necrotic myocardium.    
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Other causes of elevated troponin are myocarditis, pericarditis, 
cardiac contusion/trauma, aortic dissection, endocarditis, post cardiac 
arrest, pulmonary embolism, cardiac arrhythmia, sepsis, renal failure. 
Creatine kinase MB: 
Creatine kinase MB can be used as a alternative assay in the 
absence of cardiac troponin assay. Even improve test system for 
quantitative determination of creatine kinase MB based on 
immunological determination did not substantially increase the sensitivity 
for detection of minor myocardial injury. 
 Other biomarkers: 
 C-reactive proteins and BNP assay can be used for risk 
stratification but there is no clear guidance available for specific 
therapeutic maneuvers in the setting of myocardial infarction in response 
to these biomarkers. 
Other laboratory investigations: 
Serum lipid profile should be done in all patients with acute 
myocardial infarction within 24hours of symptoms. Ratio of total 
cholesterol to HDL cholesterol is no longer used for risk assessment. 
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Elevation in WBC count usually occurs after 2 hours of chest pain, 
reaches the peak 2 to 4 days after infarct and returns to normal range in 7 
days. increased  risk of  adverse outcome are seen in patients with higher 
WBC count in patients with acute MI. The haemoglobin value at time of 
admission with myocardial infarction independently predicts major 
cardiovascular events.  
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RISK STRATIFICATION : 
Whereas risk factors for the development of atherothrombosis 
provides in insights into disease mechanism and the opportunity for 
primary and secondary prevention therapy, analysis of risk for adverse 
outcome after   presentation is important in guiding management and 
therapeutic decisions. 
Analysis usually uses a combination of various clinical, ECG and 
biochemical parameter. Five simple baseline parameter can be used to 
predict  30-day mortality more than  90% of patients: 
1. Age. 
2. Systolic blood pressure. 
3. Killip class. 
4. Heart rate. 
5. Localisation of infarct. 
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KILLIP CLASSIFICATION 
 KILLIP class was proposed by Thomas killip III and John Kimball 
in 1967 involved bedside stratification. This risk stratification  was based 
on bedside clinical examination in patients with acute myocardial 
infarction and it is used to identify who are at highest risk of death and 
potential benefits of specialised care in intensive coronary care unit.20   
 Killip I: with no clinical signs of heart failure. 
 Killip II: with rales in the lungs, third heart sound (S3), and 
elevated jugular venous pressure 
 Killip III: with acute pulmonary edema (APE). 
 Killip IV: with cardiogenic shock or arterial hypotension 
(measured as systolic blood pressure < 90 mmHg), and evidence of 
peripheral vasoconstriction (oliguria, cyanosis, and diaphoresis). 
The  30 day mortality rate of killip class are 
Killip I: 6% of mortality. 
Killip II: 17% of mortality. 
Killip III: 38% of mortality. 
Killip IV: 81% of mortality.20  
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The other classification used in acute myocardial infarction are 
 Simplified forrester & Diamond hemodynamic 
classification(STEMI). 
 The GRACE risk score for Acute Coronary syndrome (not 
STEMI alone).  
 TIMI(The Thrombolysis In Myocardial Infarction)  score. 
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SIMPLIFIED FORRESTER CLASSIFICATION 
 
TIMI SCORE. 
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The Grace risk score for ACS: 
GRACE score calcultes mortality rate in hospital and 6 month in 
acute coronary syndrome. 
It uses data like  
 Enzyme elevation.  
 Pci done/ not. 
 Serum creatinine. 
 Killip class. 
 ST depression. 
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INFARCT LOCATION 
 Prognosis of myocardial infarction is also related to extent of 
myocardium at risk and also site of coronary occlusion.the ECG 
reflects the infarct location( TABLE 2). Patients with left main 
stem occlusion rarely reaches the hospital for reperfusion therapy. 
 Occlusion of proximal left anterior descending artery proximal to 
first septal branch is assocated with high early and late mortality ( 
window- maker).  
 Large inferior wall myocardial infarction result of dominant right 
coronary artey occlusion are also a  high risk especially when right 
ventricle is involved. 
 Other location such as apical due to distal left anterior descending 
artery, lateral myocardial infarction due to diagonal branch 
occlusion or  small inferior wall infarction due to distal right or 
circumflex occlusion have better outcome. 
 Strictly posterior wall myocardial infarction may escape routine 
ECG leads or evident only by st depression in V1- V4 usually have 
a good outcome.  
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TREATMENT 
Treatment of STEMI: 
PRE HOSPITAL CARE:  
In STEMI, pre hospital care has a very important role because 
many deaths occur within one hour of onset that usually results from 
ventricular fibrilliation. So immediate of resuscitative action and quick 
transportation to hospital is very important. Emergency medical service 
system should have three components: emergency medical dispatch, first 
response and EMS ambulance service. The EMS should have expanded 
capability to record a pre hospital 12- lead ECG.     
GENERAL TREATMENT: 
Aspirin: 
Aspirin is very effective in all acute coronary syndrome. It is initial 
management strategy for all patients with suspected STEMI. In order to 
achieve therapeutic blood level,162 to 325 mg tablet should be chewed to 
increase buccal absorption. 
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Pain management: 
Most commonly used analgesics in myocardial infarction are 
morphine, pentazocine, mepiridine. The ideal dose of morphine in 
STEMI is 4 to 8mg in intravenous route repeated at interval of 5 to 15 
minutes. It also has beneficial effect in acute pulmonary edema because 
of peripheral arterial and venous dilatation. 
Nitrates: 
Their ability to enhance blood flow of coronaries and to decrease 
preload by venodilation, sublingual nitrates are indicated in acute 
coronary syndrome once hypotension and right ventricular infarct were 
ruled out. 
Beta blockers: 
This drug reduces the pain, prevent life threatening arrhythmia, and 
also reduces infarct size. Beta blockers are contraindicated in patients 
with hypotension, bradycardia or patients with significant heart block. 
Metoprolol is common drug used in this category. 
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Oxygen: 
Hypoxemia is common in STEMI due to ventilation-perfusion 
abnormality as a sequelae of left ventricular failure. So patients should be 
treated with oxygen for a period of 24 to 48 hours. Patients with severe 
pulmonary edema may need endotracheal intubation and mechanical 
ventilation in order to correct hypoxemia.  
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Reperfusion therapy: 
Fibrinolysis: 
It recanalizes the coronary artery thrombotic occlusion, thereby it 
resore the coronary flow and reduces infarct size. Fibrinolysis improves 
both short term and long term survival.     
Assessment of reperfusion done by TIMI flow grade, TIMI frame 
count, electrocardiogram, echocardiography. 
TIMI flow grade-when assessed after 60 to 90 minutes after 
fibrinolytic therapy TIMI grade 3 has lowest mortality and grade 0 and 1 
has highest mortality. 
In ECG, resolution of ST segment is a strong predictor of positive 
outcome. 
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CONTRAINDICATION FOR FIBRINOLYTICS 
Absolute contraindication are 
 Previous intracranial hemorrhage (ICH). 
 History of structural cerebral vascular lesion. 
 History of  intracranial malignancy. 
 Ischemic stroke within  3 month of period. 
 Suspicion of aortic dissection. 
 Active  hemorrhage or bleeding diathesis (excluding menses). 
 History of  head injury or facial injury within 3 months. 
  Recent Intracranial, intraspinal surgery within 2 months. 
 Severe  uncontrolled hypertension ,not responding to 
emergency management. 
 For streptokinase, prior treatment in previous 6 months. 
Relative contraindication are 
 History of intracranial pathology. 
 Previous ischaemic stroke > 3 months. 
 Recent history of trauma. 
 Prolonged CPR more than 10 minutes. 
 Major surgery < 3 weeks. 
 Active peptic ulcer disease. 
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 Recent internal bleeding within 2 to 4 weeks. 
 Systolic BP >180, Diastolic > 110mm Hg. 
 History of severe or poorly controlled blood pressure. 
 Dementia. 
 History of non compressible vascular puncture such as IJV and  
subclavian lines. 
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Percutaneous coronary intervention(PCI): 
Current recommendations according to ACC/AHA guidelines in STEMI: 
Primary PCI  
 symptoms of STEMI within 12 hours. 
 Severe heart failure and cardiogenic shock 
 Contraindications for thrombolysis with symptoms of  STEMI  
Delayed PCI: 
 Fibrinolytic failure 
 Hemodynamically stable stenosis after 24 hours of symptoms. 
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Treatment of  NSTEMI: 
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Complications of myocardial infarction: 
Complication of acute myocardial infarction include mechanical, 
ischemic, arrhythmic, embolic and inflammatory. 
Circulatory failure, one of the mechanical complications is the mos 
common cause of death in acute myocardial infarction. 
Mechanical complications: 
 Cardiac failure. 
 Cardiogenic shock. 
 Mitral  valve regurgitation. 
 Papillary muscle dysfunction. 
 Ventricular septal rupture. 
 Free wall rupture. 
Ischemic: 
 Angina. 
 Reinfarction. 
 Extension of infarct. 
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Arrhythmic complication: 
 Atrial and ventricular arrhythmia . 
 Sino nodal or AV nodal dysfunction. 
 
Embolic complication: 
 Peripheral and central nervous system embolism. 
Inflammatory: 
 Pericarditis. 
 Dressler’s syndrome. 
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SERUM URIC ACID IN ACUTE MYOCARDIAL 
INFARCTION 
Uric acid-production and metabolism: 
 Uric acid production and metabolism is a complex processes 
involving various factors that regulate hepatic production, as well 
as renal and gut excretion of this compound. 
 Uric acid is the end product of exogenous and endogenous purine 
metabolism.19 
  The exogenous pool varies significantly with diet, and animal 
proteins contribute significantly to purine pool 
 The endogenous production of uric acid is mainly produced from  
the liver, intestines and other tissues like muscles,kidneys and the 
vascular endothelium. 
 The  chemical formula of Uric acid is  C5H4N4O3 (7,9-dihydro-
1H-purine-2,6,8(3H)-trione) 
 Molecular weight of uric acid is 168 Da.19 
 Various enzymes are involved in the conversion of the two purine 
nucleic acids, adenine and guanine, to uric acid. 
 First step, adenosinemonophosphate (AMP) is converted to inosine 
by two different mechanisms; either by removal of  an amino group 
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by deaminase to form inosine monophosphate (IMP)  then 
followed by dephosphorylation with nucleotidase to form inosine, 
or by removal of  a phosphate group by nucleotidase to form 
adenosine then followed by deamination to form inosine. 
 Guanine monophosphate (GMP) is converted to guanosine by the 
enzyme nucleotidase. 
  The nucleosides, inosine and guanosine, then converted to purine 
base hypoxanthine and guanine, respectively by enzyme purine 
nucleoside phosphorylase (PNP). 
 Hypoxanthine is then oxidized to form xanthine by enzyme  
xanthine-oxidase(XO), and guanine is deaminated to form xanthine 
by the enzyme guanine deaminase. 
 Xanthine is again oxidized by xanthine oxidase to form the final 
product, uric acid.  
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 At physiologic pH, uric acid is a weak acid with  pKα of 5.8. Uric 
acid exists majorly as urate, which is the salt of uric acid. When 
urate concentration increases in blood, uric acid crystal formation 
increases.  
 The normal value of uric acid in human blood is 1.5 to 6.0mg/dL in 
women and 2.5 to 7.0 mg/dL in men.  
 The solubility of uric acid in water is low, and in humans, the 
average concentration of uric acid in blood is close  to the solubility 
limit (6.8 mg/dL). When the level of uric acid is higher than 6.8 
mg/dL, crystals of uric acid form as monosodium urate (MSU).19 
 Uric acid concentration can be measured in serum, plasma, urine 
and also in exhaled breath condensate. 
 Various methods are 
1.  phosphotungistic acidmethods (PTA). 
2.  Uricase methods. 
3. High-performance liquid chromatography methods. 
4. Dry chemistry systems and biosensor methods. 
 The production and catabolism of purines are relatively constant 
between 300 and 400 mg per day. Two third of uric acid is excreted 
by kidney and remaining one third is excreted by gastrointestinal 
tract. 
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URIC ACID AND CARDIOVASCULAR DISEASE 
 
An association between high uric acid and cardiovascular disease 
has been reported in the 19th century itself. Since then number of studies 
have been conducted and supported this relationship and considered uric 
acid as an independent risk factor for cardiovascular events, such as 
coronary vascular disease, cerebrovascular disease, and congestive heart 
failure in high risk population (subjects with diabetes mellitus, 
hypertension, hyperlipidemia) However, the importance of a link between 
high uric acid and cardiovascular events in the general population still 
remains to be clarified. 
 
Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH  et al repored a 
study involving a large group of patients with hypertension and/or 
diabetes, a serum uric acid level more than 7 mg/dl was associated with 
increased cardiovascular mortality12. 
 
Hyperuricemia is also significantly correlated with an increased 
mortality rate in patients with congestive heart failure in some studies.11 
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URIC ACID IN ACUTE MYOCARDIAL INFARCTION:  
 Many studies were conducted in various places to prove the 
association of  uric acid in acute myocardial infarction in predicting 
mortality and severity. Some studies have shown close relationship 
between serum uric acid and killip class in acute myocardial  infarction. 
1.  C.-W. Liu et al. / International Journal of Cardiology 226 (2017)
 Relationship of serum uric acid and Killip class on mortality after 
acute ST-segment elevation myocardial infarction and primary 
percutaneous coronary intervention.Hyperuricemia increased the1-
year mortalityof STEMI  patients in Killip class I, but not of  
patients in Killip classes II–IV. An interaction of hyperuricemia and 
Killip class significantly affects the mortality of STEMI patient. 
2. Study of serum uric acid level in patients of acute myocardial 
infarction 1Dr.Anil Katdare, 2 Dr.A.L.Kakrani, 3Dr.Sridevi, 4 
Dr.Vivek Vilas Manade. This hospital based case study was 
performed in the parent institute. A total of 75cases of Acute MI 
were studied. Mean SUA for discharged  patients  was 4.67  ±1.95   
/dl and it was 7.1±1.45  mg/dl for the patients who died in the 
hospital. There was correlation between serum uric acid level after 
acute myocardial infarction and age and body mass index. 
 60 
The causes of increased serum uric acid level in acute myocardial 
infarction:  
 Uric acid are produced in endothelium by rapid degradation of  
adenosine which is synthesized  in vascular smooth muscle, then 
undergo rapid efflux to the vascular lumen due to low intracellular 
pH and negative membrane potential. 
 The activity of xanthine oxidase and production of uric acid is 
increased in ischaemic condition hence elevated uric acid can be 
used as a marker of tissue ischaemia.10 
 Hyperuricaemia is also associated with some harmful effects on 
endothelial dysfunction, oxidative metabolism, platelet 
adhesiveness, haemorheology, and aggregation. 
 Some study suggest that uric acid may  also have a negative effect 
on cardiovascular disease by causing inflammation, which is 
clearly involved in the pathogenesis of cardiovascular disease. 
 Uric acid, as a general marker of cell death and hyperuricemia is 
associated with obesity, dyslipidemia, hypertension, insulin 
resistance, male gender, aging, menopause, excessive alcohol 
intake and diuretic use. 
 Elevated Uric acid level reflects increased xanthine oxidase 
pathway activity, which has the ability to contribute in  the 
progression of left ventricular dysfunction by interfering with 
myocardial energetics and myofilament calcium sensitivity. 
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SUMMARY 
 
   Acute myocardial infarction is life threatening condition. Prompt 
action is essential as it has very high mortality in hospital and long term 
mortality and morbidity. So risk stratification forms the crux of 
management protocol since physicians has to know which patients are 
likely to develop serious and life threatening complications. 
 
Killip class is a bed side assessment test which is useful in 
predicting mortality in acute myocardial infarction. Hyperuricemia is 
associated in increased cardiovascular mortality in high risk patients. 
There are few studies which states the association between killip class 
and uric acid level.So our goal is to find out the any quantal relationship 
between killip class and serum uric acid in acute myocardial infarction in 
our population. 
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MATERIALS AND METHODS 
STUDY DESIGN:  
  Cross sectional study (Descriptive) 
STUDY PERIOD: 
 Data collection done for a period of 6 months between april 2017 
to september 2017 
PLACE OF STUDY: 
 Govt.Kilpauk Medical College and hospital,  Chennai-10. 
STUDY POPULATION: 
 Patients >18 years of age with STEMI or non-ST segment 
elevation MI (NSTEMI) on the basis of history, clinical examination, 
electrocardiographical changes and biochemical markers.    
SAMPLE SIZE : 70 
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INCLUSION CRITERIA : 
Patients >18 years of age with -STEMI or non-ST segment 
elevation MI (NSTEMI) on the basis of history, clinical examination, 
electrocardiographical changes and biochemical markers. 
1. History ( resting chest pain lasting more than30 min) 
2. Electrocardiographical changes 
 New or presumed new significant ST-segment T-wave (ST-
T) changes or new left bundle branch block 
(LBBB),Development of pathologic Q waves in the 
electrocardiogram(ECG) 
3.  Imaging evidence of new loss of viable myocardium or new 
regional wall motion abnormality  
4. Biochemical markers:  
 Rise of serum cardiac enzymes concentration (CK-MB and 
Troponins). 
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EXCLUSION CRITERIA : 
 Patients with a condition known to elevate SUA level (eg, 
chronic kidney disease, gout, hematological malignancy, 
hypothyroidism, hyperparathyroidism)  
 Patients taking drugs that increase SUA 
salicylates [>2 g/day], ethambutol, amiloride, bumetanide, 
chlorthalidone, cisplatin, cyclophosphamide, cyclosporine, 
ethacrynic acid, thiazide diuretics, furosemide, indapamide, 
isotretinoin, ketoconazole, levodopa, metolazone, 
pentamidine, phencyclidine, pyrazinamide, theophylline, 
vincristine or vitamin C. 
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METHODOLOGY  
 Patients more than 18  years of age diagnosed to have acute MI 
who presented to hospital within 24 hours of onset of symptoms 
were included in the Study. 
 Patient with increased myocardial enzyme concentrations with 
typical chest pain persisting more than 30 minutes with 
1.  electrocardiographic changes (including ischemic ST-
segment depression,  ST-segment elevation or pathologic Q 
waves). 
2.  Increased enzyme concentrations were defined as ( Creatine 
kinase,Troponin) peak level more than 2 times upper limit of 
normal. 
 Complete history taking and physical examinations was done, 
patient with exclusion criteria was identified and excluded in the 
study.After getting informed consent from the patient, they were 
included in study. 
 The data of each patient  will be collected in a special 
proforma,which includes patient’s name, age, sex,demographic 
details and presenting complaints. 
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 Blood pressure,random sugar,urea,creatinine will be taken 
immediately after admission,killip classification applied at the time 
of admissions. 
 Baseline Serum Uric acid level will be done by withdrawing 4ml of 
blood.uric acid level in serum is measured by uricase method with 
COBRA INTEGRA/COBAS C SYSTEM. 
 Cardiac enzyme assay were done in patients with NSTEMI. 
 Reference level for uric acid 
Male -3.1-7.0 mg/dl 
Female- 2.5 to 5.6 mg/dl 
 The data of each patient will be collected in specific 
proforma(ANNEXURE 2) which includes patient’s name, age, sex, 
demographic details, presenting complaints, risk factors and all 
clinical data.  
 All the relevant data and values are then entered in master chart in 
Microsoft excel format an then analyzed statiscially. 
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STATISTICAL ANALYSIS 
 The data was collected in the master chart obtained in the 
Microsoft excel format. 
 The collected was analysed with SPSS 16.0 version. To 
describe about the data descriptive statistics frequency analysis, 
percentage analysis were used for categorical variable and the mean 
were used for continuous variable. To find the significant of two 
variables by unpaired t test. To find the correlation between the two 
variables kruskal wallis test were used with p value less than .05 is 
considered as significant. 
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RESULTS 
 The total patients recruited in our study were 70. The following 
charts depicit frequency distributions. 
 These are the frequency distributions of various variable used in 
our study. 
GENDER: 
 In a total of 70 patients participated in our study 44 patients were 
male and 26 patients were females. This distribution shows the 
predominance of males in acute myocardial infarction. 
GENDER 
 Frequency Percent 
 
F 26 37.1 
M 44 62.9 
Total 70 100.0 
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 MALE 62% 
FEMALE  38% 
GENDER DISTRIBUTION 
 70 
 
ASSOCIATION BETWEEN SERUM URIC ACID AND GENDER: 
 
Mean uric acid levels was more among males (5.59) and less 
among females (4.6). This difference is statistically significant by 
unpaired t test.(p=0.004) 
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AGE DISTRIBUTION: 
 N Minimum Maximum Mean Std. 
Deviation 
AGE 70 35 69 53.77 8.054 
Valid N 
(listwise) 
70 
    
 
The mean age of the patients in our study is 54years. The minimum 
age of patient is 35years in our study.  
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DISTRIBUTION OF DIABETES: 
 
 In a total of 70 patients,46 patients were diabetes and 24 were non 
diabetic. It clearly shows acute myocardial infarction are common in 
diabetes patients. 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
 
N 24 34.3 34.3 34.3 
Y 46 65.7 65.7 100.0 
Total 70 100.0 100.0  
 
 
 
66% 
34% 
DIABETES DISTRIBUTION 
DIABETES NON DIABETES
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DISTRIBUTION OF HYPERTENSION: 
 In total of 70 patients included in our study 49 patients were 
hypertensive ant the remaining 21 patients were not hypertensive. 
HYPERTENSION 
 
 Frequency Percent Valid Percent Cumulative 
Percent 
 
NO 21 30.0 30.0 30.0 
YES 49 70.0 70.0 100.0 
Total 70 100.0 100.0  
 
 
70% 
30% 
HYPERTENSION DISTRIBUTION 
HYPERTENSION
NON
HYPERTENSIVE
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Association between serum uric acid  hypertension  / diabetes 
Kruskal-Wallis Test 
 
Variable Mean serum 
uric acid 
Std. 
Deviation 
Mean 
Rank 
P value 
Both diabetes and 
hypertension present 
5.546429 1.5469162 39.07 
 
Either diabetes or 
hypertension present 
5.030769 1.3442184 33.05 
0.485 
No hypertension / 
diabetes 
4.766667 .4163332 34.00 
 
Total 5.225714 1.4173547   
 
No significant association was found between mean serum uric 
acid levels and presence of diabetes or hypertension by kruskal wallis test 
(p=0.485) 
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SMOKING DISTRIBUTION: 
 Out of 70 patients in our study,37 patients had smoking habits and 
remaining   33 were non smokers. Out of 44 male patients 37 were 
smokers. 
SMOKING 
 Frequency Percent Valid 
Percent 
Cumulative Percent 
 
N 37 52.9 52.9 52.9 
Y 33 47.1 47.1 100.0 
Total 70 100.0 100.0  
 
  
 
37; 53% 
33; 47% 
SMOKING 
SMOKERS
NON SMOKERS
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ACUTE MYOCARDIAL INFARCTION TYPES:   
AWMI: Anterior wall myocardial infarction. 
LWMI: Lateral wall myocardial infarction. 
IWMI: Inferior wall myocardial infarction. 
NSTEMI: Non ST elevation myocardial infarction.  
 
 
0 5 10 15 20 25 30 35
AWMI
AWMI/LWMI
IWMI
NSTEMI
NO OF PATIENTS
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 Out of 70 patients, 33 patients had AWMI,8 patients were both 
AWMI/LWMI, 24 patients were IWMI,5 patients had NSTEMI. 
AWMI/IWMI/LWMI/NSTEMI 
 Frequency Percent Valid 
Percent 
Cumulative 
Percent 
Vali
d 
AWMI 33 47.1 47.1 47.1 
AWMI/LWMI 8 11.4 11.4 58.6 
IWMI 24 34.3 34.3 92.9 
NSTEMI 5 7.1 7.1 100.0 
Total 70 100.0 100.0  
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KILLIP CLASSIFICATION: 
KILLIP CLASS 
 Frequency Percent Valid Percent Cumulative 
Percent 
 
      
CLASS I 41 58.6 58.6 58.6 
CLASS II 15 21.4 21.4 80.0 
CLASS III 8 11.4 11.4 91.4 
CLASS IV 6 8.6 8.6 100.0 
Total 70 100.0 100.0  
 
 
 
CLASS I 
59% 
CLASS II 
21% 
CLASS III 
11% 
CLASS IV 
9% 
KILLIP CLASS 
CLASS I
CLASS II
CLASS III
CLASS IV
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 Out of 70 patients in our study killip class I and II was around 
80%, killip class III and IV was around 20% 
Association between serum Uric Acid levels and Killip classification: 
Killip class Mean Mean Rank P value 
I 4.475 25.06 0.000 
II 5.253 38.33 
III 7.250 62.06 
IV 7.583 64.33 
 
 
0 1 2 3 4 5 6 7 8
KILLIP I
KILLIP II
KILLIP III
KILLIP IV
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Kruskal-Wallis Test 
 Ranks  
 Killip class 
coded 
N Mean Mean 
Rank 
P value 
SERUM URIC 
ACID 
1.00 41 4.475610 25.06  
2.00 15 5.253333 38.33 0.000 
3.00 8 7.250000 62.06  
4.00 6 7.583333 64.33  
Total 70 5.225714   
 
Uric acid level was significantly higher among patients in class IV 
(7.58), in class III(7.25) than patients class II (5.25) and class I (4.47). 
Mean difference was statistically significant by kruskal wallis test 
(p=0.000). 
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DISCUSSION 
 Acute myocardial infarction is a spectrum of disorder which 
include ST elevation myocardial infarction (STEMI) and non ST 
elevation myocardial infarction( NSTEMI).STEMI is usually associated 
with short term and as well long term mortality. The diagnosis of STEMI 
and NSTEMI is done by clinical features and characteristic ECG changes 
such as new onset or presumed new changes in ST segment and new 
onset LBBB and elevation of cardiac biomarkers such as troponin I and 
T, creatine kinase MB.  
 Acute myocardial infarction is associated with high death rate 
within 24 hours. And most of the death occur within one hour of onset of 
symptoms. So  risk stratification has a important role in the management 
of acute myocardial infarction. Blood pressure, localisation of infarct, 
killip class, TIMI score are some methods useful in risk stratification and 
estimation of mortality in intensive coronary unit. 
 Killip classification is bedside evaluation test to predict the 
mortality in acute coronary syndrome. It has 4 class in which class III and 
IV has a higher mortality than the class I and II. The mortality rate of  
killip class IV is 81%. The other scores such as TIMI( Thrombolysis In 
Myocardial Infarction) was used to predict mortality in only in STEMI.20 
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 Serum uric acid is a product of purine metabolism and 
hyperuricemia is also a independent risk factor for cardiovascular disease 
in high risk population such as diabetes, hypertension, dyslipidemia.13 
Some studies shows that uric acid level more than 7gm/dl are associated 
with the high mortality rate in cardiac failure.11 In Japan, study conducted 
on STEMI patients reported that hyperuricemia increases 1-year mortality 
rate in killip class IV.22 Our study is conducted to assess the relationship 
between serum uric acid level and killip class in acute myocardial 
infarction. 
 In our study total of 70 patients were included, who were admitted 
in ICCU. All patients were included in study after getting consent, detail 
history and physical examination and after ruling out the exclusion 
criteria. Out of 70 patients 44 patients were male and 26 patients were 
females. This distribution shows the predominance of males in acute 
myocardial infarction. This results are similar to other study regarding 
male predominance in acute myocardial infarction. 
 Uric acid of male patients is significantly higher than the female 
patient, which is similar to other studies. In our study the risk factors such 
as diabetes, hypertension, smoking were taken into consideration. Out of 
70 patients 49 patients were hypertensive and 46 patients has diabetes, 37 
patients had smoking habits, smoking is common in males in our 
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population. Out of 70 patients in our study 33 patients had AWMI,8 
patients were both AWMI/LWMI, 24 patients were IWMI,5 patients had 
NSTEMI. 
 Out of 70 patients in our study, 80% of the patients were under 
killip class I and II at the time of admission, 20% of the patients were on 
killip class III and IV at the time of admission. Uric acid level was 
significantly higher among patients in class IV (7.58), in class III (7.25) 
than patients class II (5.25) and class I (4.47). Mean difference was 
statistically significant by kruskal wallis test (p=0.000). The results in our 
study shows that serum uric acid level are high in killip class III and IV in 
acute myocardial infarction patients. Combination of serum acid and 
killip classification will be useful in assessing the prognosis in acute 
myocardial infarction patients.    
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CONCLUSION 
 In general, serum uric acid level is significantly higher in male 
patients than the female patients. 
 Diabetes and hypertension remains the major risk factors for acute 
myocardial infarction. 
 Hyperuricemia is associated with killip class III and IV in Acute 
myocardial infarction patients. 
  Further study on combination of killip class and serum uric acid 
level in predicting mortality will be informative and useful. 
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PROFORMA 
 
Name                       Age:                                           Sex  
Educational status:                                                    Occupation: 
 Address:  
Ht in cms 
Wt in kgs: 
BMI [kg/m2]:   
Clinical presentation on admission:  
Time of onset of symptoms:  
 Chest pain Typical/Atypical  
 Syncope.   
 Palpitation.  
 Shortness of breath.  
 Cerebral symptoms.  
• PAST HISTORY:                        yes                       no 
• Diabetes 
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• Hypertension 
• Myocardal infarction 
• Angina pectoris 
• Cerebrovascular diseases 
• Drug intake  
• PERSONAL HISTORY:   
• Diet: vegetarian/non vegetarian: 
• Smoking/ Alcohol /Tobacco chewing: 
• Sedentary habits:  
• Menstrual and Obstetric History: 
• GENERAL EXAMINATION   
•           VITALS        PR:         BP:            JVP : 
•         Anemia:  
•          Jaundice   
•         Cyanosis:  
•          Clubbing:   
•           EDEMA  
 EXAMINATION OF CARDIOVASCULAR SYSTEM  
• EXAMINATION OF RESPIRATORY SYSTEM: 
• ABDOMEN EXAMINATION 
• CENTRAL NERVOUS SYSTEM 
 91 
  
 92 
INVESTIGATIONS 
• ECG:                                                                      ECHO 
• CBC: 
• CARDIAC ENZYMES: 
• RFT: 
• LFT: 
• SERUM URIC ACID LEVEL:  
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S.NO NAME AGE SEX HT DM SMOKING AWMI/IWMI/LWMI/NSTEMI KILLIP CLASS SERUM URIC ACID 
1 SIVAKUMAR 48 M N Y Y AWMI CLASS I 4.9 
2 ABRAHAM 58 M Y Y N IWMI CLASS I 4.6 
3 SRIDHAR 45 M N N Y IWMI CLASS I 4.3 
4 ABDUL RAHIM 35 M Y Y Y IWMI CLASS I 3.3 
5 AROKIAMARY 69 F Y N N IWMI CLASS I 5.6 
6 RAVIKUMAR 52 M N Y N AWMI CLASS I 4.1 
7 MURUGAN 55 M Y Y Y AWMI/LWMI CLASS II 6.2 
8 SARASWATHI 61 F Y Y N AWMI CLASS II 3.4 
9 PRAKASH 35 M N N Y AWMI CLASS I 4.9 
10 SUBBAIYA 49 M Y Y N IWMI CLASS I 4 
11 TAMILARASI 52 F Y Y N AWMI CLASS I 4 
12 KANNAN 51 M Y N Y AWMI CLASS I 4.1 
13 LATHA 60 F Y Y N AWMI/LWMI CLASS II 6.2 
14 DURAISAMY 55 M N Y Y AWMI CLASS I 4.3 
15 ILAYARAJA 52 M Y N Y AWMI CLASS I 6.6 
16 VENKATESAN 61 M Y Y N AWMI/LWMI CLASS IV 7.6 
17 KUMARESAN 54 M Y Y Y AWMI CLASS II 6.1 
18 RAJAMMAL 58 F Y Y N IWMI CLASS I 5.8 
19 CHELLAYA 51 M N Y Y NSTEMI CLASS I 4.4 
20 SHANMUGAM 48 M Y Y Y IWMI CLASS I 4.2 
21 RAJASEKAR 62 M Y N Y AWMI/LWMI CLASS II 5.8 
22 KUMAR 48 M N N Y IWMI CLASS I 5.1 
23 LOGANATHAN 62 M Y N Y AWMI CLASS I 4.8 
24 LAKSHMI 56 F Y N N IWMI CLASS I 3.9 
25 PERUMAL 60 M Y N Y IWMI CLASS I 4 
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26 SEETHALAKSHMI 68 F Y Y N AWMI CLASS I 4.2 
27 KALAISELVI 55 F N Y N AWMI CLASS I 3.4 
28 NANDHAGOPAL 63 M Y Y Y AWMI CLASS III 6.8 
29 GANGAIAMMAL 51 F Y Y N AWMI/LWMI CLASS III 7.8 
30 KUMAR 35 M N Y Y AWMI CLASS I 6.9 
31 KAMALAMMAL 54 F Y Y N IWMI CLASS II 3.8 
32 GOMATHI 66 F Y Y N AWMI CLASS I 3.4 
33 PARAMESHWARAN 51 M Y Y Y AWMI/LWMI CLASS II 4.8 
34 LAKSHMINARAYAN 68 M Y N Y AWMI CLASS IV 8.1 
35 PUSPHALATHA 51 F Y N N IWMI CLASS I 4.2 
36 CHELLAPPAN 60 M Y N Y AWMI CLASS II 4.3 
37 ANBALAGAN 54 M Y Y N AWMI CLASS II 4.8 
38 VALLI 49 F N Y N IWMI CLASS I 2.8 
39 NAGARAJ 54 M Y N Y AWMI CLASS I 4.1 
40 MOHAMED JINNA 58 M Y N Y IWMI CLASS I 4.8 
41 VASUKI 59 F Y Y N AWMI CLASS I 3.8 
42 DHARMARAJ 40 M Y N Y AWMI CLASS I 4.3 
43 GOVUNDRAJ 49 M Y Y Y AWMI/LWMI CLASS IV 7.2 
44 RANI 54 F Y N N IWMI CLASS II 5.1 
45 KAUVERI 66 F N Y N IWMI CLASS I 5 
46 DURAISAMY 50 M Y Y Y AWMI CLASS II 5.5 
47 KOMALA 49 F N Y N IWMI CLASS I 4 
48 RAJESHWARI 60 F Y N N NSTEMI CLASS I 3.4 
49 GOPI 54 M Y Y Y AWMI/LWMI CLASS IV 7.8 
50 KATHIRVEL 38 M N Y Y AWMI CLASS I 4.8 
51 BHAVANI 65 F Y N N NSTEMI CLASS I 3.2 
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52 GUNASEKAR 55 M Y Y N AWMI CLASS II 5.2 
53 SENTHIKUMAR 48 M N Y Y IWMI CLASS II 5.5 
54 MAHADEVAN 53 M Y Y N AWMI CLASS III 6.5 
55 JAGATHAMBAL 61 F Y Y N AWMI CLASS I 6 
56 ESWARI 56 F Y N N IWMI CLASS IV 6.4 
57 SHANTHI 50 F N Y N IWMI CLASS I 4.2 
58 KANNAN 39 M N Y Y IWMI CLASS I 4 
59 MEENAKSHI 56 F N Y N AWMI CLASS I 3.8 
60 DEVARAJ 57 M Y Y Y AWMI CLASS III 7.5 
61 GOPAL 47 M Y N Y AWMI CLASS III 7 
62 SARSWATHI 58 F Y Y N NSTEMI CLASS I 6.4 
63 SRINIVASAN 62 M Y Y N IWMI CLASS IV 8.4 
64 RAVI 40 M N Y Y AWMI CLASS III 7.8 
65 RAMACHANDRAN 51 M Y N N AWMI CLASS II 6.1 
66 AMBIKA 55 F N Y N IWMI CLASS I 5.1 
67 MANICKAM 53 M N Y N AWMI CLASS III 6.8 
68 VEERAMANI 61 M Y N N IWMI CLASS II 6 
69 JOSEPH 40 M N Y Y AWMI CLASS III 7.8 
70 ANTHONIAMMAL 64 F Y N N NSTEMI CLASS I 4.8 
          
    
HT-HYPERTENSION 
    
    
DM- DIABETES MELLITUS 
   
    
Y-YES 
     
    
N-NO 
     
       
AWMI-ANTERIOR WALL MYOCARDIAL INFARCTION 
       
IWMI-INFERIOR WALL MYOCARDIAL INFARCTION 
       
LWMI- LATERAL WALL MYOCARDIAL INFARCTION 
       
NSTEMI-NON ST ELEVATION MYOCARDIAL INFARCTION 
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PATIENT CONSENT FORM 
 
Study detail:    “correlation between Serum Uric acid level and killip 
class in acute myocardial infarction ” 
 
Study centre  :             KILPAUK  MEDICAL COLLEGE, CHENNAI 
Patients Name  : 
Patients Age  : 
Identification Number        : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered 
to my complete satisfaction. 
 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research 
that may be conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study. 
 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well-being or 
any unexpected or unusual symptoms. 
 
I hereby consent to participate in this study. 
 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological tests. 
 
 
Signature/thumb impression:    
 
 
Patients Name and Address:                   place   date 
 
 
Signature of investigator :    
 
 
Study investigator’s Name :                               place   date      
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